Fresenius nets FDA breakthrough stamp for dialysis system designed to prevent blood clots

Dialysis machine
In March, the FDA granted Fresenius a breakthrough designation to its control software being developed to provide personalized recommendations for fluid management during dialysis procedures. (Image: Getty/porpeller)

Fresenius Medical Care received a breakthrough device designation from the FDA for a new hemodialysis system that is designed to prevent blood clots internally, without requiring patients to take blood thinning medications.

The device includes an anti-thrombogenic polymer, named Endexo, which is added during the manufacturing of dialyzers and blood flow lines.

Endexo is made of “surface-modifying macromolecules” that aim to block platelets and proteins from sticking to and coating solid surfaces, according to Fresenius. This could potentially reduce the risks of blood clots, the company said, while also increasing the biocompatibility of its dialysis systems.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We are hopeful this new system will help eliminate the reliance on heparin during dialysis to improve treatments for most patients,” said Robert Kossmann, chief medical officer for Fresenius Medical Care North America, who described the companies’ work as years in the making.

RELATED: Fresenius forms new global medical office to coordinate R&D and practice sharing

Developed by the Toronto, Canada-based Interface Biologics, Endexo is permanently incorporated into the devices’ surfaces as they are produced. The material has also been used in central venous catheters and ports developed by AngioDynamics, which received FDA clearances in 2012 and 2013, to help reduce the incidence of deep vein thrombosis and activations of the body’s clotting response—as well as neurological catheters developed by Arkis BioSciences.

Meanwhile, Fresenius holds an exclusive worldwide license to apply Endexo to various hemodialysis components. Though Interface Biologics sold its medtech materials business to Evonik in early September, it retains its collaboration with Fresenius.

RELATED: Invizius raises £2.75M for its protein coating that hides dialysis machines from the immune system

This is the second breakthrough device label for Fresenius this year: In March, the FDA granted the designation to control software designed to provide personalized recommendations for fluid management, while monitoring a patient’s relative blood volume during dialysis procedures.

Fresenius said it plans to present research from the new Endexo-containing system’s development in November during the American Society of Nephrology’s Kidney Week.

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.